{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T05:08:53Z","timestamp":1755925733103},"reference-count":63,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T00:00:00Z","timestamp":1357689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0053668","type":"journal-article","created":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T00:12:19Z","timestamp":1357776739000},"page":"e53668","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Combination of a Proteomics Approach and Reengineering of Meso Scale Network Models for Prediction of Mode-of-Action for Tyrosine Kinase Inhibitors"],"prefix":"10.1371","volume":"8","author":[{"given":"Stefan","family":"Balabanov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Venz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunhild","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Scharf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"Pospisil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Braig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Barett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Walther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schuppert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,1,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature04874","article-title":"Mechanisms of drug inhibition of signalling molecules","volume":"441","author":"JS Sebolt-Leopold","year":"2006","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases [mdash] the major drug targets of the twenty-first century?","volume":"1","author":"P Cohen","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrd1066","article-title":"Issues and progress with protein kinase inhibitors for cancer treatment","volume":"2","author":"J Dancey","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/bj20021535","article-title":"The specificities of protein kinase inhibitors: an update","volume":"371","author":"J Bain","year":"2003","journal-title":"The Biochemical journal"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"MW Karaman","year":"2008","journal-title":"Nat Biotech"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1158\/1535-7163.MCT-08-0826","article-title":"Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors","volume":"7","author":"P Ross-Macdonald","year":"2008","journal-title":"Molecular Cancer Therapeutics"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase interaction map for clinical kinase inhibitors","volume":"23","author":"MA Fabian","year":"2005","journal-title":"Nat Biotech"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2007.11.037","article-title":"Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma","volume":"53","author":"N Bhojani","year":"2008","journal-title":"European urology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.3816\/CLM.2008.s.003","article-title":"Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"8","author":"A Quintas-Cardama","year":"2008","journal-title":"Clinical lymphoma & myeloma"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrd3252","article-title":"Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes","volume":"10","author":"T Force","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"B Al-Lazikani","year":"2012","journal-title":"Nat Biotechnol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1471-2105-12-169","article-title":"Predicting drug side-effect profiles: a chemical fragment-based approach","volume":"12","author":"E Pauwels","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/cmb.2010.0255","article-title":"An algorithmic framework for predicting side effects of drugs","volume":"18","author":"N Atias","year":"2011","journal-title":"J Comput Biol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1158\/0008-5472.CAN-11-2333","article-title":"A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy","volume":"72","author":"G Jin","year":"2012","journal-title":"Cancer research"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e16382","DOI":"10.1371\/journal.pone.0016382","article-title":"Identification of candidate small-molecule therapeutics to cancer by gene-signature perturbation in connectivity mapping","volume":"6","author":"DG McArt","year":"2011","journal-title":"PloS one"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"96ra77","DOI":"10.1126\/scitranslmed.3001318","article-title":"Discovery and preclinical validation of drug indications using compendia of public gene expression data","volume":"3","author":"M Sirota","year":"2011","journal-title":"Science translational medicine"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Fukuzaki M, Seki M, Kashima H, Sese J (2009) Side Effect Prediction Using Cooperative Pathways. Proceedings of the 2009 IEEE International Conference on Bioinformatics and Biomedicine: IEEE Computer Society. 142\u2013147.","DOI":"10.1109\/BIBM.2009.26"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/msb4100116","article-title":"Chemical combination effects predict connectivity in biological systems","volume":"3","author":"J Lehar","year":"2007","journal-title":"Mol Syst Biol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e8919","DOI":"10.1371\/journal.pone.0008919","article-title":"Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling","volume":"5","author":"M Peifer","year":"2010","journal-title":"PloS one"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/nchembio817","article-title":"Systems biology and combination therapy in the quest for clinical efficacy","volume":"2","author":"JB Fitzgerald","year":"2006","journal-title":"Nat Chem Biol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e1002323","DOI":"10.1371\/journal.pcbi.1002323","article-title":"Prediction of drug combinations by integrating molecular and pharmacological data","volume":"7","author":"XM Zhao","year":"2011","journal-title":"PLoS Comput Biol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1126\/science.1081900","article-title":"Inferring Genetic Networks and Identifying Compound Mode of Action via Expression Profiling","volume":"301","author":"TS Gardner","year":"2003","journal-title":"Science"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1038\/nprot.2006.300","article-title":"The mode-of-action by network identification (MNI) algorithm: a network biology approach for molecular target identification","volume":"1","author":"H Xing","year":"2006","journal-title":"Nature protocols"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nbt1075","article-title":"Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks","volume":"23","author":"D di Bernardo","year":"2005","journal-title":"Nature biotechnology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nbt1397","article-title":"A modular approach for integrative analysis of large-scale gene-expression and drug-response data","volume":"26","author":"Z Kutalik","year":"2008","journal-title":"Nature biotechnology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e1000591","DOI":"10.1371\/journal.pcbi.1000591","article-title":"Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data","volume":"5","author":"A Mitsos","year":"2009","journal-title":"PLoS computational biology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2190-5983-1-6","article-title":"Efficient reengineering of meso-scale topologies for functional networks in biomedical applications","volume":"1","author":"A Schuppert","year":"2011","journal-title":"Journal of Mathematics in Industry"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/imamat\/hxn011","article-title":"Local identification of scalar hybrid models with tree structure","volume":"73","author":"B Fiedler","year":"2008","journal-title":"IMA Journal of Applied Mathematics"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Schopfer G, Kahrs O, Marquardt W, Warncke M, Mrziglod T, <etal>et al<\/etal>.. (2005) Semi-empirical process modelling with integration of commercial modelling tools; Espu\u00f1a LPaA, editor. Barcelona, Spain. 595\u2013600 p.","DOI":"10.1016\/S1570-7946(05)80221-4"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Schuppert A (1999) Extrapolability of structured hybrid models: A key to the optimization of complex processes.; Fiedler B, Groeger K, Sprekels J, editors. Singapore: World Scientific Publishing.","DOI":"10.1142\/9789812792617_0218"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"R Ren","year":"2005","journal-title":"Nature reviews Cancer"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"BJ Druker","year":"2006","journal-title":"The New England journal of medicine"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"G Saglio","year":"2010","journal-title":"The New England journal of medicine"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"H Kantarjian","year":"2010","journal-title":"The New England journal of medicine"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, <etal>et al<\/etal>.. (2011) Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive CML patients with resistance or intolerance to imatinib. Blood.","DOI":"10.1182\/blood-2011-05-355594"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1586\/ehm.09.42","article-title":"Bosutinib: a dual SRC\/ABL kinase inhibitor for the treatment of chronic myeloid leukemia","volume":"2","author":"G Keller","year":"2009","journal-title":"Expert review of hematology"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Cortes JE, Kim D-W, Kantarjian HM, Br\u00fcmmendorf TH, Dyagil I, <etal>et al<\/etal>.. (2012) Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial. Journal of Clinical Oncology.","DOI":"10.1200\/JCO.2011.38.7522"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1182\/blood-2007-09-113175","article-title":"Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I","volume":"111","author":"A Gontarewicz","year":"2008","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-3-47","article-title":"First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib","volume":"3","author":"G Wei","year":"2010","journal-title":"Journal of hematology & oncology"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1158\/1078-0432.CCR-09-3314","article-title":"Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia","volume":"17","author":"T O'Hare","year":"2011","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"T O'Hare","year":"2009","journal-title":"Cancer cell"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1158\/0008-5472.CAN-07-1825","article-title":"Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358","volume":"67","author":"M Modugno","year":"2007","journal-title":"Cancer research"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1162\/artl.2009.Winkler.011","article-title":"Predictive mesoscale network model of cell fate decisions during C. elegans embryogenesis","volume":"15","author":"DA Winkler","year":"2009","journal-title":"Artificial life"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jtbi.2004.04.037","article-title":"A computational algebra approach to the reverse engineering of gene regulatory networks","volume":"229","author":"R Laubenbacher","year":"2004","journal-title":"Journal of theoretical biology"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0092-8674(00)00015-5","article-title":"Functional discovery via a compendium of expression profiles","volume":"102","author":"TR Hughes","year":"2000","journal-title":"Cell"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"J Lamb","year":"2006","journal-title":"Science"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nmeth0910-681","article-title":"Mass spectrometry in high-throughput proteomics: ready for the big time","volume":"7","year":"2010","journal-title":"Nature methods"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nbt1328","article-title":"Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors","volume":"25","author":"M Bantscheff","year":"2007","journal-title":"Nature biotechnology"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"U Rix","year":"2007","journal-title":"Blood"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1021\/pr1008527","article-title":"Proteomics analysis of cellular imatinib targets and their candidate downstream effectors","volume":"9","author":"SB Breitkopf","year":"2010","journal-title":"Journal of proteome research"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"7414","DOI":"10.1073\/pnas.0900653106","article-title":"Charting the molecular network of the drug target Bcr-Abl","volume":"106","author":"M Brehme","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood-2005-03-037648","article-title":"Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach","volume":"109","author":"S Balabanov","year":"2007","journal-title":"Blood"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.cellsig.2009.12.012","article-title":"The Bcr-Abl kinase regulates the actin cytoskeleton via a GADS\/Slp-76\/Nck1 adaptor protein pathway","volume":"22","author":"C Preisinger","year":"2010","journal-title":"Cell Signal"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1182\/blood-2004-05-2041","article-title":"Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells","volume":"105","author":"F Guo","year":"2005","journal-title":"Blood"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood.V96.6.2284","article-title":"Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex","volume":"96","author":"Y Shiotsu","year":"2000","journal-title":"Blood"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00726-010-0500-z","article-title":"Transglutaminase 2: a multi-functional protein in multiple subcellular compartments","volume":"39","author":"D Park","year":"2010","journal-title":"Amino Acids"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"HJ Khoury","year":"2012","journal-title":"Blood"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"ME Gorre","year":"2001","journal-title":"Science"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"NP Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"e16833","DOI":"10.1371\/journal.pone.0016833","article-title":"Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform","volume":"6","author":"R Ummanni","year":"2011","journal-title":"PloS one"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1021\/pr201172n","article-title":"Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro","volume":"11","author":"R Ummanni","year":"2012","journal-title":"Journal of proteome research"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1021\/pr300170p","article-title":"Proteomic profiling of germ cell cancer cells treated with aaptamine, a marine alkaloid with antiproliferative activity","volume":"11","author":"SA Dyshlovoy","year":"2012","journal-title":"J Proteome Res"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"e43468","DOI":"10.1371\/journal.pone.0043468","article-title":"Expression of Eukaryotic Initiation Factor 5A and Hypusine Forming Enzymes in Glioblastoma Patient Samples: Implications for New Targeted Therapies","volume":"7","author":"M Preukschas","year":"2012","journal-title":"PloS one"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0053668","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T04:09:08Z","timestamp":1595218148000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0053668"}},"subtitle":[],"editor":[{"given":"Thomas","family":"H\u00f6fer","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,1,9]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0053668","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,9]]}}}